Survival benefit with resection of brain metastases from renal cell carcinoma in the setting of molecular targeted therapy and/or immune therapy

2021 ◽  
pp. 100805
Author(s):  
Kristin Huntoon ◽  
Mark Damante ◽  
Joshua Wang ◽  
Thomas Olencki ◽  
J. Bradley Elder
Keyword(s):  
Renal Cell Carcinoma ◽  
Targeted Therapy ◽  
Brain Metastases ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Survival Benefit ◽  
Molecular Targeted Therapy ◽  
Immune Therapy

FDG PET/CT after first molecular targeted therapy predicts survival of patients with renal cell carcinoma

2018 ◽  
Vol 81 (4) ◽  
pp. 739-744 ◽  
Author(s):  
Noboru Nakaigawa ◽  
Keiichi Kondo ◽  
Tomohiro Kaneta ◽  
Ukihide Tateishi ◽  
Ryogo Minamimoto ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Targeted Therapy ◽  
Cell Carcinoma ◽  
Fdg Pet ◽  
Renal Cell ◽  
Molecular Targeted Therapy ◽  
Pet Ct ◽  
Fdg Pet Ct

Sub-classification of patients with intermediate-risk metastatic renal cell carcinoma treated with targeted therapy

2019 ◽  
Vol 49 (8) ◽  
pp. 780-785
Author(s):  
Go Kaneko ◽  
Suguru Shirotake ◽  
Koshiro Nishimoto ◽  
Yasumasa Miyazaki ◽  
Keiichi Ito ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Targeted Therapy ◽  
High Risk ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Molecular Targeted Therapy ◽  
Laboratory Data ◽  
Original Model

Abstract Background International Metastatic Renal Cell Carcinoma Database Consortium model predicts the outcomes of metastatic renal cell carcinoma stratified into favorable, intermediate, and poor risk groups (FG, IG, and PG, respectively), with approximately 50% of patients being classified as IG. We aimed to generate better risk model based on the sub-classification of IG. Methods We analyzed records of 213 consecutive patients receiving molecular targeted therapy. Age, gender, histology, type of initial molecular targeted therapy, serum laboratory data, previous nephrectomy and immunotherapy, and metastatic sites were used for IG sub-stratification. Modified and original models were compared using a concordance correlation coefficient analysis. Results Median follow-up was 17.8 months. Serum albumin, serum C-reactive protein, and bone metastases were independent predictors of overall survival (OS) in IG. IG was sub-classified into low-, middle-, and high-risk IG according to the number of predictors. The following modified model was developed: modified FG (FG & low-risk IG), modified IG (middle-risk IG), and modified PG (PG & high-risk IG). Concordance indices for original and modified models were 0.68 and 0.73, respectively (P < 0.001). OS was significantly longer in modified PG treated with mammalian target of rapamycin inhibitors as second-line therapy than with tyrosine kinase inhibitors, whereas this was not observed in the original model. Conclusions We successfully developed modified IMDC model using a two-step process: the original IMDC plus an IG sub-stratification, and demonstrated that it predicts outcomes more accurately than original model.

Course of size and density of metastatic renal cell carcinoma lesions in the early follow-up of molecular targeted therapy

2012 ◽  
Vol 30 (5) ◽  
pp. 695-703 ◽  
Author(s):  
Markus Hittinger ◽  
Michael Staehler ◽  
Nicolai Schramm ◽  
Christopher Übleis ◽  
Christoph Becker ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Targeted Therapy ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Molecular Targeted Therapy

scholarly journals Multimodality treatment of brain metastases from renal cell carcinoma in the era of targeted therapy

2016 ◽  
Vol 8 (6) ◽  
pp. 450-459 ◽  
Author(s):  
Maria Bassanelli ◽  
Antonella Viterbo ◽  
Michela Roberto ◽  
Silvana Giacinti ◽  
Anita Staddon ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Targeted Therapy ◽  
Brain Metastases ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Multimodality Treatment
Sign in / Sign up

Export Citation Format

Share Document